Skip to main content
SpringerLink
Log in

Comment on “Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?”

  • Letter to the Editor
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Veal FC, Peterson GM. Pain in the frail or elderly patient: does tapentadol have a role? Drugs Aging. 2015;32(6):419–26. doi:10.1007/s40266-015-0268-7.

    Article  CAS  PubMed  Google Scholar 

  2. Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015; 5:CD009923. doi:10.1002/14651858.CD009923.pub2.

  3. Riemsma R, Forbes C, Harker J, Worthy G, Misso K, Schäfer M, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin. 2011;27:1907–30. doi:10.1185/03007995.2011.611494.

    Article  CAS  PubMed  Google Scholar 

  4. Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin. 1997;35:25–32.

    CAS  PubMed  Google Scholar 

  5. Zautra AJ, Smith BW. Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain. 2005;21:471–7.

    Article  PubMed  Google Scholar 

  6. van Ojik AL, Jansen PA, Brouwers JR, van Roon EN. Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Drugs Aging. 2012;29:615–25. doi:10.2165/11632620-000000000-00000.

    Article  PubMed  Google Scholar 

  7. Hubbard RE, O’Mahony MS, Woodhouse KW. Medication prescribing in frail older people. Eur J Clin Pharmacol. 2013;69:319–26. doi:10.1007/s00228-012-1387-2.

    Article  PubMed  Google Scholar 

  8. Obradovic M, Ikenberg R, Hertel N, Antoñanzas F, Gálvez R, Liedgens H. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin Ther. 2012;34:926–43. doi:10.1016/j.clinthera.2012.02.011.

    Article  PubMed  Google Scholar 

  9. Ikenberg R, Hertel N, Moore RA, Obradovic M, Baxter G, Conway P, et al. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ. 2012;15:724–36. doi:10.3111/13696998.2012.670174.

    Article  PubMed  Google Scholar 

  10. Holdsworth MT, Forman WB, Killilea TA, Nystrom KM, Paul R, Brand SC, et al. Transdermal fentanyl disposition in elderly subjects. Gerontology. 1994;40:32–7.

    Article  CAS  PubMed  Google Scholar 

  11. Moore RA. What works for whom? Determining the efficacy and harm of treatments for pain. Pain. 2013;154(Suppl 1):S77–86. doi:10.1016/j.pain.2013.03.024.

    Article  Google Scholar 

  12. Attal N. Pharmacologic treatment of neuropathic pain. Acta Neurol Belg. 2001;101:53–64.

    CAS  PubMed  Google Scholar 

  13. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174:1589–94.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113. doi:10.1111/j.1468-1331.2010.02999.x.

    Article  CAS  PubMed  Google Scholar 

  15. Zekry O, Aggarwal A. Tapentadol: are we hitting two birds with one stone? APS newsletter; 2013, pp 2–4. https://www.apsoc.org.au/PDF/Newsletters/FEB13_APS_news_0213_v02.pdf. Accessed 30 Sept 2015

  16. Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth. 2014;113:148–56. doi:10.1093/bja/aeu056.

    Article  CAS  PubMed  Google Scholar 

  17. Gregorian RS Jr, Gasik A, Kwong WJ, Voeller S, Kavanagh S. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010;11:1095–108. doi:10.1016/j.jpain.2010.02.007.

    Article  PubMed  Google Scholar 

  18. Gálvez R, Schäfer M, Hans G, Falke D, Steigerwald I. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Ther. 2013;30:229–59. doi:10.1007/s12325-013-0015-6.

    Article  PubMed  Google Scholar 

  19. Sánchez Del Águila MJ, Schenk M, Kern KU, Drost T, Steigerwald I. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther. 2015;37:94–113. doi:10.1016/j.clinthera.2014.07.005.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology and Geriatric Medicine, Department of Medicine, University of Western Australia, Crawley, WA, 6009, Australia

    Charles A. Inderjeeth

  2. Suite G174B, C Block, Rehabilitation and Aged Care, Queen Elizabeth II Medical Centre, Hospital Avenue, Nedlands, WA, 6009, Australia

    Charles A. Inderjeeth

  3. Pain Education Unit, Faculty of Medicine, Sydney Medical School, Royal North Shore Hospital, University of Sydney, St Leonards, NSW, 2006, Australia

    Olfat Zekry

Authors
  1. Olfat Zekry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles A. Inderjeeth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olfat Zekry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zekry, O., Inderjeeth, C.A. Comment on “Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?”. Drugs Aging 32, 871–873 (2015). https://doi.org/10.1007/s40266-015-0313-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-015-0313-6

Keywords

Search

Navigation